Clinical Trial Detail

NCT ID NCT03699475
Title Study of Haplo-HSCT + BPX-501 vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bellicum Pharmaceuticals
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

BPX-501 + Rimiducid

Cyclophosphamide

Age Groups: adult senior

No variant requirements are available.